Patents by Inventor Guo-Yun Chen

Guo-Yun Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
    Patent number: 8637013
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: The Regents of The University of Michigan
    Inventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xincheng Zheng, Xi Cheng, Steve Kunkel
  • TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD-24-HMGB1-SIGLEC10 AXIS
    Publication number: 20120201819
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Application
    Filed: March 21, 2012
    Publication date: August 9, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Yang LIU, Pan ZHENG, Guo-Yun CHEN, Xi CHEN, Steve KUNKEL, Xincheng ZHENG
  • Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
    Patent number: 8163281
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: April 24, 2012
    Assignee: The Regents Of The University Of Michigan
    Inventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xincheng Zheng, Xi Chen, Steve Kunkel
  • TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS
    Publication number: 20110064746
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Application
    Filed: March 3, 2010
    Publication date: March 17, 2011
    Inventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xi Chen, Steve Kunkel, Xincheng Zheng